Abstract
Difluoromethylornithine (DFMO) is an irreversible enzyme-activated inhibitor of ornithine decarboxylase, a key enzyme in polyamine synthesis. We have screened for potential anti-cancer activity of DFMO using a clonogenic assay, which suggested that melanoma might have sensitivity to this agent. Accordingly, we have performed a phase II trial of DFMO (2 g/m2 po q 8 h) in 24 patients, 21 of whom were evaluable for response. One patient achieved a complete response of a large subcutaneous mass for 11 months. Although stabilization is frequently difficult to measure, seven patients appeared to stabilize previously active disease, with a median duration of response of eight weeks. Toxicity was significant and DFMO was discontinued in five patients due to side effects — hearing loss alone in four and hearing loss associated with thrombocytopenia in the fifth patient. Hearing changes occurred in ten patients. Other side effects were mild. These data indicate that DFMO as a single agent may be an effective therapy for melanoma. A phase II trial of DFMO in previously untreated patients using a different schedule to decrease hearing loss is warranted. Additionally, several in vitro and animal models suggest that DFMO plus interferon are synergistic, and this combination might be used for a clinical trial as well.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Comis RL: DTIC (NSC-45388) in malignant melanoma: a perspective. Cancer Treat Rep 60:165–176, 1976
Mamont PS, Duchesne M, Juder-Ohlenbusch A, Grove J: Effects of ornithine decarboxylase inhibitors on cultured cells. In: Seller N, Jung MJ, Koch-Weser J (eds): Enzyme-activated irreversible inhibitors, Vol. 3. Elsevier/North- Holland Biomedical Press, Amsterdam, 1978, pp 43–53
Metcalf BW, Bey P, Danzin C, Jung MJ, Casara P, Vevert JP: Catalytic irreversible inhibition of mammalian ornithine decarboxylase (EC 4.1.1.17) by substrate and product analogues. J Am Chem Soc 100:2551–2553, 1978
Pegg AE, McCann PP: Polyamine metabolism and function. Am J Physiol 243 (Cell Physiol 12):C212-C221, 1982
Mamont PS, Duchesne MC, Grove J, Bey J: Antiproliferative properties of D, L-α-difluoromethylornithine in cultured cells. A consequence of the irreversible inhibition of ornithine decarboxylase. Biochem Biophys Res Commun 81:58–66, 1978
Prakash NJ, Schechter PJ, Grove J, Koch-Weser J: Effect of α-difluoromethylornithine, an enzyme-activated irreversible inhibitor of ornithine decarboxylase on L1210 leukemia in mice. Cancer Res 38:3054–3062, 1978
Marton LJ, Levin VA, Hervatin SJ, Koch-Weser J, McCann PP, Sjoerdsma A: Potentiation of the antitumor therapeutic effects of 1,3-bis(2-chloroethyl)-nitrosourea by α-difluoro-methylornithine, an ornithine decarboxylase inhibitor. Cancer Res 41:4426–4431, 1981
Sano Y, Deen DF, Oredsson SM, Marton LJ: Effects of α-difluoromethyl-ornithine on the growth of 9L rat brain tumor multicellular spheroids and their response to 1,3-bis(2-chlorethyl)-1-nitrosourea. Cancer Res 144:577–581, 1984
Salmon SE, Hamburger AW, Soehnlen B, Durie BG, Alberts DS, Moon TE: Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs. N Engl J Med 298:1321–1327, 1978
Kovach JS, Svingen PA: Enhancement of the antiproliferative activity of human interferon by polyamine depletion. Cancer Treat Rep 69:97–103, 1985
Siimes M, Seppanen P, Alchonen-Hongisto L, Janne J: Synergistic action of two polyamine antimetabolites leads to a rapid therapeutic response in childhood leukemia. Inst J Cancer 28:567–570, 1981
Abeloff MD, Slavik M, Luk GD, Griffin CA, Hermann J, Blanc O, Sjoerdsma A, Baylin SB: Phase I trial and pharmacokinetic studies of α-difluoromethylornithine — an inhibitor of polyamine biosynthesis. J Clin Oncol 2:124–130, 1980
Salmon SE, Meyskens FL Jr, Alberts DS, Soehnlen B, Young L: New drugs in ovarian cancer and malignant melanoma in vitro phase II screening with the human tumor stem cell assay. Cancer Treat Rep 65:1–12, 1981
Meyskens FL Jr, Salmon SE: Inhibition of human melanoma colony formation by retinoids. Cancer Res 39:4055–4057, 1979
Salmon SE, Durie BGM, Young L, Lui RM, Trown PW, Stebbing N: Effects of cloned leukocyte interferons in the human tumor stem cell assay. J Clin Oncol 1:217–225, 1983
Natale RB, Meyer K, Forastiere A: Phase I trials of α-difluoromethyl-ornithine alone and in combination with methylglyoxal bis-guanylhydrazone. Proc ASCO 4:C-532, 1985
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Meyskens, F.L., Kingsley, E.M., Glattke, T. et al. A phase II study of α-difluoromethylornithine (DFMO) for the treatment of metastatic melanoma. Invest New Drugs 4, 257–262 (1986). https://doi.org/10.1007/BF00179593
Issue Date:
DOI: https://doi.org/10.1007/BF00179593